RGNX - REGENXBIO Inc.
| Previous Close | 57.79 |
| Open | 57.79 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 900 |
| Day's Range | 56.50 - 59.19 |
| 52 Week Range | 26.80 - 85.10 |
| Volume | 395,600 |
| Avg. Volume | 544,430 |
| Market Cap | 2.108B |
| Beta (3Y Monthly) | 0.68 |
| PE Ratio (TTM) | 21.21 |
| EPS (TTM) | 2.73 |
| Earnings Date | May 6, 2019 - May 10, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 81.50 |
- Investopedia•16 days ago
10 Stocks For The Gene Therapy Revolution
Gene therapy, which treats genetic diseases by replacing faulty genes, is a rapidly growing field, with merger activity on the rise.
- Motley Fool•18 days ago
Gene Therapy M&A Has Shares Skyrocketing -- Could This Company Be Next?
Roche and Biogen are spending big bucks on gene therapy biotech stocks.
- PR Newswire•20 days ago
REGENXBIO to Participate in Upcoming Investor Conferences
ROCKVILLE, Md. , March 6, 2019 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based ...
- Zacks•21 days ago
REGENXBIO (RGNX) in Focus: Stock Moves 5.1% Higher
REGENXBIO (RGNX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
- Motley Fool•22 days ago
3 Top Small-Cap Stocks to Buy Right Now
These three small-cap stocks have outstanding growth potential.
- Barrons.com•24 days ago
Why Big Pharma Is Diving Into Gene Therapy
Emerging revolutionary treatments promise possible cures for diseases like hemophilia and muscular dystrophy—and opportunities for investors
- Thomson Reuters StreetEvents•24 days ago
Edited Transcript of RGNX earnings conference call or presentation 27-Feb-19 9:30pm GMT
Q4 2018 Regenxbio Inc Earnings Call
Motley Fool•26 days agoRegenxbio Inc. (RGNX) Q4 2018 Earnings Conference Call Transcript
RGNX earnings call for the period ending December 31, 2018.
- PR Newswire•26 days ago
REGENXBIO Reports Fourth Quarter and Full-Year 2018 Financial Results and Recent Operational Highlights
ROCKVILLE, Md. , Feb. 27, 2019 /PRNewswire/ -- Announces updates from recently expanded RGX-314 Phase I/IIa trial for wet AMD Completed dosing of six additional subjects in the fourth cohort for a total ...
- Zacks•27 days ago
The Zacks Analyst Blog Highlights: Spark Therapeutics, Solid Biosciences, REGENXBIO, Editas Medicine and uniQure
The Zacks Analyst Blog Highlights: Spark Therapeutics, Solid Biosciences, REGENXBIO, Editas Medicine and uniQure
- Zacks•28 days ago
5 Gene Therapy Stocks to Enrich Your Portfolio
Gene therapy stocks have not only soared on Roche-Spark deal news but are also poised to make the most of the next gene revolution.
- PR Newswire•last month
REGENXBIO to Host Conference Call on February 27 to Discuss Fourth Quarter and Full-Year 2018 Financial Results and Recent Operational Highlights
ROCKVILLE, Md. , Feb. 20, 2019 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based ...
- PR Newswire•last month
REGENXBIO to Host RGX-314 Program Analyst and Investor Event with Leading Retina Specialists
ROCKVILLE, Md. , Feb. 14, 2019 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based ...
- GlobeNewswire•2 months ago
Market Trends Toward New Normal in Keysight Technologies, Alamos Gold, ADT, SecureWorks, REGENXBIO, and Tetra Technologies — Emerging Consolidated Expectations, Analyst Ratings
NEW YORK, Feb. 04, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- PR Newswire•2 months ago
REGENXBIO Receives Rare Pediatric Disease Designation for RGX-181 Gene Therapy for the Treatment of CLN2 Form of Batten Disease
ROCKVILLE, Md., Jan. 31, 2019 /PRNewswire/ -- REGENXBIO Inc. (RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced the U.S. Food and Drug Administration (FDA) granted Rare Pediatric Disease Designation to RGX-181. RGX-181 is a one-time treatment candidate for late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease, one of the most common forms of Batten disease caused by mutations in the tripeptidyl peptidase 1 (TPP1) gene.
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of RGNX earnings conference call or presentation 7-Nov-18 9:30pm GMT
Q3 2018 Regenxbio Inc Earnings Call
- Simply Wall St.•2 months ago
REGENXBIO Inc. (NASDAQ:RGNX): Time For A Financial Health Check
REGENXBIO Inc. (NASDAQ:RGNX), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. However, the trade-off is RGNX will Read More...
- PR Newswire•3 months ago
REGENXBIO to Present at the 37th Annual J.P. Morgan Healthcare Conference
ROCKVILLE, Md. , Jan. 4, 2019 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based ...
- PR Newswire•3 months ago
REGENXBIO Reports Continued Progress Across Programs in Year-End 2018 Corporate Update
REGENXBIO Inc. (RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV Technology Platform, today provided a year-end 2018 corporate update. In 2018, we received over $200 million from our partners, and we believe our strong financial position will enable us to execute on our corporate goals throughout 2019," said Kenneth T. Mills, President and Chief Executive Officer of REGENXBIO.
Market Realist•3 months agoWhy Arrowhead Pharmaceuticals Stock Rose Over 10% Yesterday
On December 12, Arrowhead Pharmaceuticals (ARWR) stock closed at $12.19, an ~11.53% rise from its previous day’s close of $13.62. Arrowhead Pharmaceuticals stock rose from $3.68 at the close of market on December 29, 2017, to reach $15.19 at the close of market on December 12, reflecting a ~313% year-to-date rise.
- Insider Monkey•3 months ago
Is Regenxbio Inc (RGNX) A Good Stock To Buy?
Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity portfolios as of the end of September. At Insider Monkey, we follow over 700 of the best-performing investors and by analyzing their 13F filings, we can determine the stocks that they are collectively bullish […]
- American City Business Journals•4 months ago
This Rockville biotech is getting some help from Maryland, MoCo for its new HQ
Rockville-based RegenxBio Inc. (NASDAQ: RGNX) locked in a new headquarters site about a month ago. Now more details have emerged about financial incentives it is receiving from Maryland and Montgomery County. The Maryland Department of Commerce approved a $700,000 conditional loan through Advantage Maryland, formerly the Maryland Economic Development Assistance Authority and Fund, and Montgomery County approved a $100,000 conditional grant, and will help expedite the permitting process for the new location, according to a release.
Market Realist•4 months agoArrowhead Pharmaceuticals Stock Has Risen ~252% Year-to-Date
Arrowhead Pharmaceuticals stock rose from $3.68 at the close of market on December 29, 2017, to $12.95 at the close of market on November 21, 2018, a ~252% rise year-to-date. On November 21, Arrowhead Pharmaceuticals closed at $12.95, ~42% below the 52-week high of $22.39 it reached on September 6. Arrowhead Pharmaceuticals hit its 52-week low of $3.01 on December 13, 2017.
